MA64323B1 - Inhibiteurs de nlrp3 - Google Patents

Inhibiteurs de nlrp3

Info

Publication number
MA64323B1
MA64323B1 MA64323A MA64323A MA64323B1 MA 64323 B1 MA64323 B1 MA 64323B1 MA 64323 A MA64323 A MA 64323A MA 64323 A MA64323 A MA 64323A MA 64323 B1 MA64323 B1 MA 64323B1
Authority
MA
Morocco
Prior art keywords
nlrp3 inhibitors
compounds
nlrp3
inhibitors
composition
Prior art date
Application number
MA64323A
Other languages
English (en)
Inventor
Georg Jaeschke
Wolfgang Guba
Lea Aurelie BOUCHE
Stefanie Katharina MESCH
Andreas Michael TOSSTORFF
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA64323B1 publication Critical patent/MA64323B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne de nouveaux composés représentés par la formule générale Ib Ib, dans laquelle R1, R2, R3, R4, R5 et Z sont tels que décrits dans la description, une composition comprenant lesdits composés et des procédés d'utilisation desdits composés.
MA64323A 2021-05-12 2022-05-10 Inhibiteurs de nlrp3 MA64323B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21173452 2021-05-12
EP21209447 2021-11-22
EP21215859 2021-12-20
EP22728228.2A EP4337652B1 (fr) 2021-05-12 2022-05-10 Inhibiteurs de nlrp3
PCT/EP2022/062525 WO2022238347A1 (fr) 2021-05-12 2022-05-10 Inhibiteurs de nlrp3

Publications (1)

Publication Number Publication Date
MA64323B1 true MA64323B1 (fr) 2025-06-30

Family

ID=81941106

Family Applications (1)

Application Number Title Priority Date Filing Date
MA64323A MA64323B1 (fr) 2021-05-12 2022-05-10 Inhibiteurs de nlrp3

Country Status (26)

Country Link
US (1) US20240208928A1 (fr)
EP (2) EP4609865A3 (fr)
JP (1) JP2024517917A (fr)
KR (1) KR20240007152A (fr)
AR (1) AR125818A1 (fr)
AU (1) AU2022275300A1 (fr)
BR (1) BR112023023527A2 (fr)
CA (1) CA3214626A1 (fr)
CL (1) CL2023003312A1 (fr)
CO (1) CO2023016204A2 (fr)
CR (1) CR20230529A (fr)
DK (1) DK4337652T3 (fr)
ES (1) ES3031704T3 (fr)
FI (1) FI4337652T3 (fr)
HR (1) HRP20250632T1 (fr)
HU (1) HUE071498T2 (fr)
IL (1) IL307188A (fr)
LT (1) LT4337652T (fr)
MA (1) MA64323B1 (fr)
MX (1) MX2023012907A (fr)
PE (1) PE20240126A1 (fr)
PL (1) PL4337652T3 (fr)
RS (1) RS66893B1 (fr)
SI (1) SI4337652T1 (fr)
TW (1) TW202311245A (fr)
WO (1) WO2022238347A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US20250152584A1 (en) * 2022-01-07 2025-05-15 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
IL320499A (en) * 2022-11-04 2025-06-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and use thereof
AU2023388532A1 (en) * 2022-12-07 2025-02-13 F. Hoffmann-La Roche Ag Novel compounds as modulators of nlrp3 inhibition
CN120603818A (zh) * 2023-01-27 2025-09-05 姆温格疗法公司 Nlrp3抑制剂
KR20250158072A (ko) * 2023-03-20 2025-11-05 인실리코 메디신 아이피 리미티드 Nlrp3 인플라마좀 억제제 및 이의 용도
CN120835880A (zh) 2023-03-23 2025-10-24 成都赜灵生物医药科技有限公司 三嗪类化合物及其用途
TW202502344A (zh) 2023-06-02 2025-01-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之5,6不飽和雙環雜環
AU2024307670A1 (en) 2023-06-29 2025-11-20 F. Hoffmann-La Roche Ag Triazine derivatives as nlrp3 inhibitors
WO2025026882A1 (fr) 2023-07-28 2025-02-06 F. Hoffmann-La Roche Ag Nouveaux composés
WO2025059069A1 (fr) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Modulateurs de nlrp3
WO2025153532A1 (fr) 2024-01-16 2025-07-24 NodThera Limited Polythérapies faisant intervenir des inhibiteurs de nlrp3 et des agonistes de glp-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3

Also Published As

Publication number Publication date
JP2024517917A (ja) 2024-04-23
IL307188A (en) 2023-11-01
LT4337652T (lt) 2025-06-25
MX2023012907A (es) 2023-11-08
EP4609865A3 (fr) 2025-10-29
HUE071498T2 (hu) 2025-09-28
AU2022275300A1 (en) 2023-09-21
CA3214626A1 (fr) 2022-11-17
CL2023003312A1 (es) 2024-06-21
KR20240007152A (ko) 2024-01-16
PE20240126A1 (es) 2024-01-22
CO2023016204A2 (es) 2023-12-11
RS66893B1 (sr) 2025-07-31
US20240208928A1 (en) 2024-06-27
SI4337652T1 (sl) 2025-07-31
HRP20250632T1 (hr) 2025-07-18
ES3031704T3 (en) 2025-07-10
PL4337652T3 (pl) 2025-07-14
BR112023023527A2 (pt) 2024-01-30
CR20230529A (es) 2023-12-04
EP4337652A1 (fr) 2024-03-20
WO2022238347A1 (fr) 2022-11-17
FI4337652T3 (fi) 2025-06-20
DK4337652T3 (da) 2025-06-10
TW202311245A (zh) 2023-03-16
EP4337652B1 (fr) 2025-04-09
AR125818A1 (es) 2023-08-16
EP4609865A2 (fr) 2025-09-03

Similar Documents

Publication Publication Date Title
MA64323B1 (fr) Inhibiteurs de nlrp3
MA53219B1 (fr) Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
MA48594B1 (fr) Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA29746B1 (fr) Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c
MA49560B1 (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
MA27725A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
MA31690B1 (fr) Nouveaux fongicides
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA31754B1 (fr) Cis-imidazolines chirales
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
MA31596B1 (fr) Nouveaux herbicides
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
MA31000B1 (fr) Derives 2-aza-bicyclo[3.1.0]hexane
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA31703B1 (fr) Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1
MA30686B1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase.
MA27569A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases